Inflammation, oxidative stress, glomerular filtration rate, and albuminuria in elderly men: a cross-sectional study

BMC Research Notes

Johan Ärnlöv³  Erik Ingelsson¹  Samar Basu⁵  Elisabeth Jobs³  Anders Larsson⁴  Johan Sundström⁶  Ulf Risérus²  Johanna Helmersson-Karlqvist⁴  Elisabet Nerpin³ 

[1] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 77, Stockholm, Sweden;Department of Public Health and Caring Sciences/Clinical Nutrition and Metabolism, Uppsala University, SE-751 85, Uppsala, Sweden;School of Health and Social Studies, Dalarna University, SE-79188, Falun, Sweden;Clinical chemistry, University hospital, SE-751 85, Uppsala, Sweden;Biochimie, Biologie Moléculaire et Nutrition, Faculté de Pharmacie, Université d'Auvergne, Clermont-Ferrand, 63001, Clermont-Ferrand cedex 1, France;Uppsala Clinical Research Centre, Uppsala University, SE-752 37, Uppsala, Sweden

关键词: Glomerular filtration rate and albuminuria;    Oxidative stress;    Inflammation;   

Others  :  1165569
DOI  :  10.1186/1756-0500-5-537

 received in 2012-05-05, accepted in 2012-09-22,  发布年份 2012

【 摘 要 】

Background

The role of inflammation and oxidative stress in mild renal impairment in the elderly is not well studied. Accordingly, we aimed at investigating the associations between estimated glomerular filtration rate (eGFR), albumin/creatinine ratio (ACR), and markers of different inflammatory pathways and oxidative stress in a community based cohort of elderly men.

Findings

Cystatin C-based GFR, ACR, and biomarkers of cytokine-mediated inflammation (interleukin-6, high-sensitivity C-reactive protein[CRP], serum amyloid A[SAA]), cyclooxygenase-mediated inflammation (urinary prostaglandin F2α [PGF2α]), and oxidative stress (urinary F2 isoprostanes) were assessed in the Uppsala Longitudinal Study of Adult Men(n = 647, mean age 77 years).

Results

In linear regression models adjusting for age, BMI, smoking, blood pressure, LDL-cholesterol, HDL-cholesterol, triglycerides, and treatment with statins, ACE-inhibitors, ASA, and anti-inflammatory agents, eGFR was inversely associated with CRP, interleukin-6, and SAA (β-coefficient −0.13 to −0.19, p < 0.001 for all), and positively associated with urinary F2-isoprostanes (β-coefficient 0.09, p = 0.02). In line with this, ACR was positively associated with CRP, interleukin-6, and SAA (β- coefficient 0.09-0.12, p < 0.02 for all), and negatively associated with urinary F2-isoprostanes (β-coefficient −0.12, p = 0.002). The associations were similar but with lower regression coefficients in a sub-sample with normal eGFR (>60 ml/min/1.73 m2, n = 514), with the exception that F2-isoprostane and SAA were no longer associated with eGFR.

Conclusion

Our data indicate that cytokine-mediated inflammation is involved in the early stages of impaired kidney function in the elderly, but that cyclooxygenase-mediated inflammation does not play a role at this stage. The unexpected association between higher eGFR/lower albuminuria and increased F2-isoprostanes in urine merits further studies.

【 授权许可】

   
2012 Nerpin et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005, 16:489-495.
• [2]Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629-636.
• [3]Coresh J, Longenecker JC, Miller ER 3rd, Young HJ, Klag MJ: Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998, 9:S24-S30.
• [4]Muntner P, He J, Astor BC, Folsom AR, Coresh J: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005, 16:529-538.
• [5]McCullough PA, Soman SS, Shah SS, Smith ST, Marks KR, Yee J, Borzak S: Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000, 36:679-684.
• [6]Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, Shyr Y, Himmelfarb J: Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 2002, 58:190-197.
• [7]Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002, 62:1524-1538.
• [8]Keller CR, Odden MC, Fried LF, Newman AB, Angleman S, Green CA, Cummings SR, Harris TB, Shlipak MG: Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int 2007, 71:239-244.
• [9]Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004, 65:1009-1016.
• [10]Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D: Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006, 48:752-760.
• [11]Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B: Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005, 293:1737-1745.
• [12]Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C: Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005, 67:2330-2337.
• [13]Basu S: Novel cyclooxygenase-catalyzed bioactive prostaglandin F2alpha from physiology to new principles in inflammation. Med Res Rev 2007, 27:435-468.
• [14]Basu S: F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal 2008, 10:1405-1434.
• [15]Kadiiska MB, Gladen BC, Baird DD, Graham LB, Parker CE, Ames BN, Basu S, Fitzgerald GA, Lawson JA, Marnett LJ, et al.: Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Free Radic Biol Med 2005, 38:711-718.
• [16]Roberts LJ, Morrow JD: Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000, 28:505-513.
• [17]Larsson A, Malm J, Grubb A, Hansson LO: Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 2004, 64:25-30.
• [18]Basu S: Radioimmunoassay of 15-keto-13,14-dihydro-prostaglandin F2alpha: an index for inflammation via cyclooxygenase catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids 1998, 58:347-352.
• [19]Basu S: Radioimmunoassay of 8-iso-prostaglandin F2alpha: an index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids 1998, 58:319-325.
• [20]Helmersson J, Vessby B, Larsson A, Basu S: Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004, 109:1729-1734.
• [21]Pruijm M, Ponte B, Vollenweider P, Mooser V, Paccaud F, Waeber G, Marques-Vidal P, Burnier M, Bochud M: Not all inflammatory markers are linked to kidney function: results from a population-based study. Am J Nephrol 2012, 35:288-294.
• [22]Stuveling EM, Hillege HL, Bakker SJ, Gans RO, De Jong PE, De Zeeuw D: C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003, 63:654-661.
• [23]Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM: Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003, 107:87-92.
• [24]Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J: The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004, 140:9-17.
• [25]Upadhyay A, Larson MG, Guo CY, Vasan RS, Lipinska I, O'Donnell CJ, Kathiresan S, Meigs JB, Keaney JF Jr, Rong J, et al.: Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant 2011, 26:920-926.
• [26]Keller C, Katz R, Cushman M, Fried LF, Shlipak M: Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 2008, 9:9. BioMed Central Full Text
• [27]Kshirsagar AV, Bomback AS, Bang H, Gerber LM, Vupputuri S, Shoham DA, Mazumdar M, Ballantyne CM, Paparello JJ, Klemmer PJ: Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol 2008, 101:401-406.
• [28]Sabanayagam C, Lee J, Shankar A, Lim SC, Wong TY, Tai ES: C-reactive protein and microalbuminuria in a multi-ethnic Asian population. Nephrol Dial Transplant 2010, 25:1167-1172.
• [29]Cottone S, Mule G, Guarneri M, Palermo A, Lorito MC, Riccobene R, Arsena R, Vaccaro F, Vadala A, Nardi E, et al.: Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Transplant 2009, 24:497-503.
• [30]Chade AR, Best PJ, Rodriguez-Porcel M, Herrmann J, Zhu X, Sawamura T, Napoli C, Lerman A, Lerman LO: Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia. Kidney Int 2003, 64:962-969.
• [31]Cheng ZJ, Vaskonen T, Tikkanen I, Nurminen K, Ruskoaho H, Vapaatalo H, Muller D, Park JK, Luft FC, Mervaala EM: Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension 2001, 37:433-439.
• [32]Savino A, Pelliccia P, Giannini C, de Giorgis T, Cataldo I, Chiarelli F, Mohn A: Implications for kidney disease in obese children and adolescents. Pediatr Nephrol 2011, 26:749-758.
• [33]Halliwell B, Lee CY: Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxid Redox Signal 2010, 13:145-156.
• [34]Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, Blumberg JB: Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001, 59:1960-1966.
• [35]Basu S, Sjoquist B, Stjernschantz J, Resul B: Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukot Essent Fatty Acids 1994, 50:161-168.
• [36]Basu S: Metabolism of 8-iso-prostaglandin F2alpha. FEBS Lett 1998, 428:32-36.
• [37]Grubb A, Blirup-Jensen S, Lindstrom V, Schmidt C, Althaus H, Zegers I: First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin Chem Lab Med 2010, 48:1619-1621.
• [38]Blirup-Jensen S, Grubb A, Lindstrom V, Schmidt C, Althaus H: Standardization of Cystatin C: development of primary and secondary reference preparations. Scand J Clin Lab Invest 2008, 241:67-70.
• [39]Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, et al.: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012, 367:20-29.